External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech

ACR 2023

-
Coming soon
09:45 PM
Duration 90mins Ballroom 20D
Kidney-Related Outcomes and Steroid-Sparing Effects of Patients With Active Lupus Nephritis Treated With Obinutuzumab: A Post-Hoc Analysis of the Phase 2 NOBILITY Trial
Rovin B, Terres J, Giang S, Schindler T, Turchetta A, Garg J, Furie R, Pendergraft W, Malvar A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:00 PM
Duration 2hrs San Diego, USA
B-Cell Recovery in a Randomized Controlled Trial of B-Cell Depletion With Obinutuzumab for the Treatment of Proliferative Lupus Nephritis
Vital EM, Roccatello D, Black D, Jacob-Moffatt R, Looney M, Martins E, Mao H (Ashley), Schindler T, Sehgal H, Garg J, Terres J, Furie R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:00 PM
Duration 2hrs San Diego, USA
Patient-Reported Outcomes in Patients With Lupus Nephritis: A Post Hoc Analysis of Control Arm Data From Two Completed Phase III Randomized Clinical Trials
Lindsay L, Tchakoute C, Yoshida S, Wallenstein G, Terres J, Mao A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar